This treatment induced a transformation of the immunosuppressive TNBC phenotype into an immune-activated one, evidenced by the enhanced infiltration and proliferation of CD8+ T cells, CD4+ T cells, DCs, and M1 macrophages at the tumor site. This evidence concerns the gene CD8A and neoplasm.